Global  ||| S:0 E:7 ||| JJ
trends  ||| S:7 E:14 ||| NNS
in  ||| S:14 E:17 ||| IN
breast  ||| S:17 E:24 ||| JJ
cancer  ||| S:24 E:31 ||| NN
incidence  ||| S:31 E:41 ||| NN
and  ||| S:41 E:45 ||| CC
mortality  ||| S:45 E:55 ||| NN
This  ||| S:55 E:60 ||| DT
review  ||| S:60 E:67 ||| NN
highlights  ||| S:67 E:78 ||| VBZ
the  ||| S:78 E:82 ||| DT
increasing  ||| S:82 E:93 ||| JJ
incidence  ||| S:93 E:103 ||| NN
of  ||| S:103 E:106 ||| IN
breast  ||| S:106 E:113 ||| JJ
cancer  ||| S:113 E:120 ||| NN
world-wide  ||| S:120 E:131 ||| JJ
and  ||| S:131 E:135 ||| CC
the  ||| S:135 E:139 ||| DT
increasing  ||| S:139 E:150 ||| JJ
burden  ||| S:150 E:157 ||| NN
of  ||| S:157 E:160 ||| IN
breast  ||| S:160 E:167 ||| JJ
cancer  ||| S:167 E:174 ||| NN
deaths  ||| S:174 E:181 ||| NNS
experienced  ||| S:181 E:193 ||| VBN
by  ||| S:193 E:196 ||| IN
lower-income  ||| S:196 E:209 ||| JJ
countries ||| S:209 E:218 ||| NNS
.  ||| S:218 E:220 ||| .
The  ||| S:220 E:224 ||| DT
causes  ||| S:224 E:231 ||| NNS
of  ||| S:231 E:234 ||| IN
increasing  ||| S:234 E:245 ||| VBG
incidence  ||| S:245 E:255 ||| NNS
have  ||| S:255 E:260 ||| VBP
been  ||| S:260 E:265 ||| VBN
attributed  ||| S:265 E:276 ||| VBN
to  ||| S:276 E:279 ||| TO
changes  ||| S:279 E:287 ||| NNS
in  ||| S:287 E:290 ||| IN
the  ||| S:290 E:294 ||| DT
prevalence  ||| S:294 E:305 ||| NN
of  ||| S:305 E:308 ||| IN
reproductive  ||| S:308 E:321 ||| JJ
risk  ||| S:321 E:326 ||| NN
factors ||| S:326 E:333 ||| NNS
,  ||| S:333 E:335 ||| ,
lifestyle  ||| S:335 E:345 ||| JJ
changes ||| S:345 E:352 ||| NNS
,  ||| S:352 E:354 ||| ,
and  ||| S:354 E:358 ||| CC
genetic  ||| S:358 E:366 ||| JJ
and  ||| S:366 E:370 ||| CC
biological  ||| S:370 E:381 ||| JJ
differences  ||| S:381 E:393 ||| NNS
between  ||| S:393 E:401 ||| IN
ethnic  ||| S:401 E:408 ||| JJ
and  ||| S:408 E:412 ||| CC
racial  ||| S:412 E:419 ||| JJ
groups ||| S:419 E:425 ||| NNS
.  ||| S:425 E:427 ||| .
All  ||| S:427 E:431 ||| PDT
these  ||| S:431 E:437 ||| DT
factors  ||| S:437 E:445 ||| NNS
may  ||| S:445 E:449 ||| MD
contribute ||| S:449 E:459 ||| VB
,  ||| S:459 E:461 ||| ,
but  ||| S:461 E:465 ||| CC
data  ||| S:465 E:470 ||| NNS
linking  ||| S:470 E:478 ||| VBG
etiological  ||| S:478 E:490 ||| JJ
factors  ||| S:490 E:498 ||| NNS
to  ||| S:498 E:501 ||| TO
increased  ||| S:501 E:511 ||| JJ
risk  ||| S:511 E:516 ||| NN
in  ||| S:516 E:519 ||| IN
developing  ||| S:519 E:530 ||| VBG
countries  ||| S:530 E:540 ||| NNS
is  ||| S:540 E:543 ||| VBZ
lacking ||| S:543 E:550 ||| VBG
.  ||| S:550 E:552 ||| .
The  ||| S:552 E:556 ||| DT
challenge  ||| S:556 E:566 ||| NN
for  ||| S:566 E:570 ||| IN
lower-income  ||| S:570 E:583 ||| JJ
countries  ||| S:583 E:593 ||| NNS
is  ||| S:593 E:596 ||| VBZ
developing  ||| S:596 E:607 ||| VBG
effective  ||| S:607 E:617 ||| JJ
strategies  ||| S:617 E:628 ||| NNS
to  ||| S:628 E:631 ||| TO
reverse  ||| S:631 E:639 ||| VB
the  ||| S:639 E:643 ||| DT
trend  ||| S:643 E:649 ||| NN
of  ||| S:649 E:652 ||| IN
increasing  ||| S:652 E:663 ||| VBG
mortality ||| S:663 E:672 ||| NN
.  ||| S:672 E:674 ||| .
Down-staging  ||| S:674 E:687 ||| JJ
of  ||| S:687 E:690 ||| IN
breast  ||| S:690 E:697 ||| JJ
cancer  ||| S:697 E:704 ||| NN
by  ||| S:704 E:707 ||| IN
early  ||| S:707 E:713 ||| JJ
detection  ||| S:713 E:723 ||| NN
is  ||| S:723 E:726 ||| VBZ
a  ||| S:726 E:728 ||| DT
promising  ||| S:728 E:738 ||| JJ
long-term  ||| S:738 E:748 ||| JJ
strategy  ||| S:748 E:757 ||| NN
for  ||| S:757 E:761 ||| IN
preventing  ||| S:761 E:772 ||| VBG
disease-related  ||| S:772 E:788 ||| JJ
deaths  ||| S:788 E:795 ||| NNS
but  ||| S:795 E:799 ||| CC
it  ||| S:799 E:802 ||| PRP
is  ||| S:802 E:805 ||| VBZ
difficult  ||| S:805 E:815 ||| JJ
to  ||| S:815 E:818 ||| TO
make  ||| S:818 E:823 ||| VB
the  ||| S:823 E:827 ||| DT
economic  ||| S:827 E:836 ||| JJ
investment  ||| S:836 E:847 ||| NN
required  ||| S:847 E:856 ||| VBN
to  ||| S:856 E:859 ||| TO
carry  ||| S:859 E:865 ||| VB
out  ||| S:865 E:869 ||| RP
broad  ||| S:869 E:875 ||| JJ
screening  ||| S:875 E:885 ||| NN
programs ||| S:885 E:893 ||| NNS
.  ||| S:893 E:895 ||| .
Successful  ||| S:895 E:906 ||| JJ
strategies  ||| S:906 E:917 ||| NNS
for  ||| S:917 E:921 ||| IN
addressing  ||| S:921 E:932 ||| VBG
the  ||| S:932 E:936 ||| DT
growing  ||| S:936 E:944 ||| VBG
breast  ||| S:944 E:951 ||| NN
cancer  ||| S:951 E:958 ||| NN
burden  ||| S:958 E:965 ||| NN
will  ||| S:965 E:970 ||| MD
therefore  ||| S:970 E:980 ||| RB
take  ||| S:980 E:985 ||| VB
political  ||| S:985 E:995 ||| JJ
will ||| S:995 E:999 ||| NN
,  ||| S:999 E:1001 ||| ,
reliable  ||| S:1001 E:1010 ||| JJ
data ||| S:1010 E:1014 ||| NNS
,  ||| S:1014 E:1016 ||| ,
public  ||| S:1016 E:1023 ||| JJ
and  ||| S:1023 E:1027 ||| CC
medical  ||| S:1027 E:1035 ||| JJ
community  ||| S:1035 E:1045 ||| NN
awareness ||| S:1045 E:1054 ||| NN
,  ||| S:1054 E:1056 ||| ,
and  ||| S:1056 E:1060 ||| CC
partnerships  ||| S:1060 E:1073 ||| NNS
between  ||| S:1073 E:1081 ||| IN
community  ||| S:1081 E:1091 ||| NN
advocates ||| S:1091 E:1100 ||| NNS
,  ||| S:1100 E:1102 ||| ,
governments ||| S:1102 E:1113 ||| NNS
,  ||| S:1113 E:1115 ||| ,
non-governmental  ||| S:1115 E:1132 ||| JJ
organizations  ||| S:1132 E:1146 ||| NNS
and  ||| S:1146 E:1150 ||| CC
biotechnology ||| S:1150 E:1163 ||| NN
.  ||| S:1163 E:1165 ||| .
